Abacavir has no prothrombotic effect on platelets in vitro.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Journal of Antimicrobial Chemotherapy

• Publication date

  2016-12-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1093/JAC/DKW303PMID 27516475
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Evaluation of cardiovascular biomarkers in a randomized trial of fosamprenavir/ritonavir vs. efavirenz with abacavir/lamivudine in underrepresented, antiretroviral-naïve, HIV-infected patients (SUPPORT): 96-week results

  2013cited by this paper
• In vivo platelet activation and platelet hyperreactivity in abacavir-treated HIV-infected patients

  2013cited by this paper
• Endothelial and platelet function alterations in HIV-infected patients.

  2012cited by this paper
• Abacavir use and cardiovascular disease events: a meta-analysis of published and unpublished data

  2011cited by this paper
• Evaluation of cardiovascular biomarkers In HIV-infected patients switching to abacavir or tenofovir based therapy

  2011cited by this paper
• Abacavir increases platelet reactivity via competitive inhibition of soluble guanylyl cyclase

  2011cited by this paper
• Markers of inflammation and coagulation indicate a prothrombotic state in HIV-infected patients with long-term use of antiretroviral therapy with or without abacavir

  2010cited by this paper
• Platelet function and HIV: a case–control study

  2010cited by this paper
• Abacavir and didanosine induce the interaction between human leukocytes and endothelial cells through Mac-1 upregulation

  2010cited by this paper
• Association of abacavir and impaired endothelial function in treated and suppressed HIV-infected patients

  2009cited by this paper
• Risk of Myocardial Infarction and Abacavir Therapy: No Increased Risk Across 52 GlaxoSmithKline-Sponsored Clinical Trials in Adult Subjects

  2009cited by this paper
• Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients

  2008cited by this paper
• Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration.

  2008cited by this paper
• A Review of the Pharmacokinetics of Abacavir

  2008cited by this paper
• Enhanced shear-induced platelet aggregation in patients who experience subacute stent thrombosis: a case-control study.

  2005cited by this paper
• Platelets in inflammation and atherogenesis.

  2005cited by this paper
• Platelets in atherothrombosis

  2002cited by this paper
• The Calibrated Automated Thrombogram (CAT): a universal routine test for hyper- and hypocoagulability

  2002cited by this paper

• In vitro and patient studies with platelets to explore off‐target cardiovascular effects of integrase inhibitors

  2024cites this paper
• Abacavir use is associated with increased prothrombin conversion

  2023cites this paper
• Two-Drug Regimens for HIV—Current Evidence, Research Gaps and Future Challenges

  2022cites this paper
• Characterization of the impact of immune checkpoint inhibitors on platelet activation and aggregation.

  2022cites this paper
• Interactions of HIV and Antiretroviral Therapy With Neutrophils and Platelets

  2021cites this paper
• Plasmatic Coagulation Capacity Correlates With Inflammation and Abacavir Use During Chronic HIV Infection

  2021cites this paper
• Long-term treated HIV infection is associated with platelet mitochondrial dysfunction

  2021cites this paper
• HIV Antivirals Affect Endothelial Activation and Endothelial-Platelet Crosstalk

  2020cites this paper
• Pharmacological impact of antiretroviral therapy on platelet function to investigate human immunodeficiency virus‐associated cardiovascular risk

  2019cites this paper
• Platelets in Immune Response to Virus and Immunopathology of Viral Infections

  2018cites this paper
• Cardiovascular toxicity of abacavir: a clinical controversy in need of a pharmacological explanation

  2017cites this paper